Browsing Molecular Pathology by publication type "Thesis or Dissertation"
Now showing items 1-20 of 28
-
A study of the co-evolution of the genome and epigenome in colorectal cancer using multi-omics profiling
(Institute of Cancer Research (University Of London), 2021-11-30) -
A translational study in pancreatic neuroendocrine neoplasms
(Institute of Cancer Research (University Of London), 2019-11-30)Pancreatic neuroendocrine neoplasms (PanNENs) are rare, highly heterogeneous tumours. There have been significant recent advances in our knowledge of genomic events underlying their pathogenesis. However, treatment decisions ... -
Amino acid dependence in acute myeloid leukaemia
(Institute of Cancer Research (University Of London), 2022-05-31)Acute myeloid leukaemia (AML) is a heterogeneous disease which remains curable in only a minority of patients. Outcome is dismal in the subgroup with adverse genetic features. Amino acid (AA) depletion is a therapeutic ... -
Analysis of novel therapeutic options for adenoid cystic carcinoma of the salivary glands
(Institute of Cancer Research (University Of London), 2021-04-30)Adenoid cystic adenocarcinoma (ACC) of the salivary glands is characterised by slow growth, frequent metastasis and low survival rates. ACC is resistant to conventional chemotherapy and currently, no systemic agent has ... -
Applications of intertumoural, intratumoural and intermolecular heterogeneity for personalised medicine in colorectal cancer
(Institute of Cancer Research (University Of London), 2020-03-31)Colorectal cancer (CRC) is a heterogeneous disease, both at the molecular level and in the context of patients' responses to treatment. Few biomarkers are currently in place that can help to stratify patients in the clinical ... -
Circulating microRNA-652-3p as a biomarker of regorafenib resistance in metastatic colorectal cancer patients
(Institute of Cancer Research (University Of London), 2020-09-30)MicroRNAs (miRNAs) are small non-coding RNAs involved in cell homeostasis. MiRNAs dysregulation has been linked with activation of oncogenic pathways, cancer progression and clinical outcome in metastatic colorectal cancer ... -
Clinical and co-clinical genomics of paediatric solid tumours with a special focus in DIPG
(Institute of Cancer Research (University Of London), 2020-07-31)Cure rates for paediatric solid cancers have not improved in the last decade. Delivering precision medicine to stratify patients based on their molecular profiling is a key goal to support existing and upcoming adaptive ... -
The comprehensive proteomic characterisation of soft tissue sarcoma
(Institute of Cancer Research (University Of London), 2023-01-04)Soft tissue sarcomas (STS) are a group of rare and heterogeneous mesenchymal malignancies. The extensive clinical and biological heterogeneity of STS complicates clinical disease management, and in the advanced setting ... -
Deciphering the genomic landscape and evolution in multiple myeloma
(Institute of Cancer Research (University Of London), 2020-09-30)Multiple myeloma (MM) is the second commonest haematological cancer in Western countries, with most patients dying from progressive disease after relapse. Currently, the molecular mechanisms responsible for the initiation ... -
Deconstructing the soft tissue sarcoma matrisome and adhesome for drug target and biomarker discovery
(Institute of Cancer Research (University Of London), 2023-12-08)Soft tissue sarcomas (STS) are a rare and diverse group of mesenchymal malignancies that present significant challenges in clinical management due to their extensive clinical and biological heterogeneity. STS have a dismal ... -
Defining the mechanisms of multi-target tyrosine kinase inhibitor resistance in soft tissue sarcoma
Soft tissue sarcomas (STS) are a rare, heterogeneous, and challenging group of cancers to treat effectively. The approval of pazopanib, as well as promising clinical trial data for a number of other multi-target tyrosine ... -
Defining the role of SF3B1K700E mutations in ER+ breast cancer
(Institute of Cancer Research (University Of London), 2021-09-30)Mutations in SF3B1, a component of the RNA splicing machinery, underpin a number of aggressive cancers. Hotspot mutations in SF3B1 are present in around 3% of breast cancers, are enriched in oestrogen receptor positive ... -
Development of biomarker assays to dissect subtype-specific heterogeneity and anti-EGFR treatment response in colorectal cancer
(Institute of Cancer Research (University Of London), 2020-08-31)Colorectal cancer (CRC) is the third most frequently diagnosed type of cancer and the second leading cause of cancer deaths worldwide. Although extensive biological heterogeneity at multiple "-omics" levels has been ... -
Genetics of high risk myeloma
(Institute of Cancer Research (University Of London), 2021-03-31)Despite significant progress in therapy in the last two decades, the outlook for multiple myeloma (MM) patients is still poor as the disease remains incurable and only 33% of patients survive for up to 10 years after ... -
Genetics of relapse and treatment resistance in multiple myeloma
(Institute of Cancer Research (University Of London), 2022-05-31)Better understanding of the mechanisms of relapse and treatment resistance in myeloma could improve clinical outcomes. Copy number aberrations (CNA) are a major feature of multiple myeloma, however their evolution over ... -
Improving the multiple myeloma patient pathway: microsampling for remote monitoring of free light chains
(Institute of Cancer Research (University Of London), 2023-01-24)Multiple myeloma (MM) is categorised as a relapsing-remitting blood cancer with unpredictable relapse patterns. Due to an inevitable relapse, blood test monitoring is crucial and requires frequent visits to the phlebotomy ... -
Investigating the mehcanisms of drug resistance in gastro-intestinal cancers
(Institute of Cancer Research (University Of London), 2020-03-31)Despite many effective therapies for gastro-intestinal (GI) cancers, both primary and acquired mechanisms of resistance commonly occur. The subclonal complexity of intra-tumoural heterogeneity in these cancers further ... -
Late recurrence in ER+ breast cancer - refining risk prediction beyond 5 years
(Institute of Cancer Research (University Of London), 2021-11-30)ER positive (ER+) breast cancer has the potential to recur many years following diagnosis. Predicting who is most at risk of recurrence and when this may occur is complex. Risk prediction incorporates clinical, pathological ... -
Mapping the dynamic immune landscape associated with therapeutic response in soft tissue sarcoma
(Institute of Cancer Research (University Of London), 2023-10-24)Soft tissue sarcomas (STS) are a group of rare and heterogenous cancers of unmet need. In the advanced setting, and following failure of first-line anthracycline therapy, further line therapeutic options offer limited ... -
Mathematical modelling of subclonal interactions in paediatric high-grade gliomas
(Institute of Cancer Research (University Of London), 2022-05-31)Despite a low overall mutational burden, paediatric high-grade gliomas (pHGG) display high intra-tumour heterogeneity. Accumulating evidence suggest the presence of cellular mechanisms that maintain such high heterogeneity, ...